Related Experiment Video
Updated: May 25, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
A potential drug-herbal interaction between Ginkgo biloba and efavirenz
Mark Naccarato1, Deborah Yoong, Kevin Gough
11Department of Medicine, Division of Infectious Diseases, St Michael's Hospital, Toronto, ON, Canada.
Abstract:
Efavirenz (EFV) is primarily metabolized by cytochrome P450 (CYP) 2B6 and to a lesser extent by CYP3A4. Drugs that significantly inhibit or induce these enzymes would then be expected to increase or lower the levels of EFV potentially resulting in toxicity or therapeutic failure, respectively. The constituents of Ginkgo biloba extract have been demonstrated to induce gene expression of the CYP450 enzymes. We report a case in which a potential drug-herb interaction may have led to virological breakthrough in a patient that was maintained on the same regimen for 10 years. Therefore, a drug-herbal interaction may be expected when these agents are taken concurrently, and we advise clinicians to avoid this combination when possible.
Related Concept Videos
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Drug toxicity: Drug–Drug Interaction
Pharmacokinetics: Drug–Drug Interactions
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Combined Effects of Drugs: Synergism
Such synergistic combinations...
